In skin cutaneous melanoma, for both anti‐PD‐1 (Pembrolizumab) and anti‐CTLA‐4 (Ipilimumab), we see responders having higher IP expression pretreatment. This evidence concerns the gene CTLA4 and cutaneous melanoma.